JP2006508995A - 血清トリグリセリド値を低下させるためのPPARαアゴニスト及びメトホルミンの使用 - Google Patents

血清トリグリセリド値を低下させるためのPPARαアゴニスト及びメトホルミンの使用 Download PDF

Info

Publication number
JP2006508995A
JP2006508995A JP2004554485A JP2004554485A JP2006508995A JP 2006508995 A JP2006508995 A JP 2006508995A JP 2004554485 A JP2004554485 A JP 2004554485A JP 2004554485 A JP2004554485 A JP 2004554485A JP 2006508995 A JP2006508995 A JP 2006508995A
Authority
JP
Japan
Prior art keywords
metformin
pparα agonist
fenofibrate
pharmaceutically acceptable
pparα
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004554485A
Other languages
English (en)
Japanese (ja)
Inventor
ジャン−ルイ ジュニアン,
アラン エドガー,
エヴリーヌ シャピュ,
Original Assignee
フルニエ ラボラトリーズ アイルランド リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by フルニエ ラボラトリーズ アイルランド リミテッド filed Critical フルニエ ラボラトリーズ アイルランド リミテッド
Publication of JP2006508995A publication Critical patent/JP2006508995A/ja
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/155Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2004554485A 2002-11-28 2003-11-26 血清トリグリセリド値を低下させるためのPPARαアゴニスト及びメトホルミンの使用 Pending JP2006508995A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02292940A EP1424070A1 (fr) 2002-11-28 2002-11-28 Combinaison d'un agoniste de PPAR-alpha et de metformine pour la réduction du taux de triglycérides sériques
PCT/EP2003/013302 WO2004047831A2 (fr) 2002-11-28 2003-11-26 Utilisation d'un agoniste pparalpha et metformine permettant de diminuer les triglycerides seriques

Publications (1)

Publication Number Publication Date
JP2006508995A true JP2006508995A (ja) 2006-03-16

Family

ID=32241358

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004554485A Pending JP2006508995A (ja) 2002-11-28 2003-11-26 血清トリグリセリド値を低下させるためのPPARαアゴニスト及びメトホルミンの使用

Country Status (22)

Country Link
US (2) US20060142397A1 (fr)
EP (2) EP1424070A1 (fr)
JP (1) JP2006508995A (fr)
CN (1) CN1777417B (fr)
AT (1) ATE362362T1 (fr)
AU (1) AU2003288175B2 (fr)
BR (1) BR0316810A (fr)
CA (1) CA2507894C (fr)
CY (1) CY1106749T1 (fr)
DE (1) DE60313886T2 (fr)
DK (1) DK1569634T3 (fr)
EA (1) EA009772B1 (fr)
ES (1) ES2287546T3 (fr)
HK (1) HK1077755A1 (fr)
MA (1) MA27553A1 (fr)
MX (1) MXPA05005707A (fr)
NO (1) NO20052549L (fr)
PT (1) PT1569634E (fr)
SI (1) SI1569634T1 (fr)
TN (1) TNSN05148A1 (fr)
WO (1) WO2004047831A2 (fr)
ZA (1) ZA200504345B (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006520365A (ja) * 2003-03-13 2006-09-07 フルニエ ラボラトリーズ アイルランド リミテッド 肥満を治療するための、フィブラート系薬剤及びオルリスタットの使用

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6414002B1 (en) 1999-09-22 2002-07-02 Bristol-Myers Squibb Company Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
EP1559419A1 (fr) * 2004-01-23 2005-08-03 Fournier Laboratories Ireland Limited Composition pharmaceutique contenant une combinaison de mefformine et d'un fibrate et les procédés pour les obtenir
FR2896160B1 (fr) * 2006-01-13 2008-04-25 Merck Sante Soc Par Actions Si Combinaison de derives de triazine et d'agonistes du ppar alpha.
US8883721B2 (en) * 2009-05-12 2014-11-11 Mcgill University Methods of inhibiting the ghrelin/growth hormone secretatogue receptor pathway and uses thereof
US9724381B2 (en) 2009-05-12 2017-08-08 The Administrators Of The Tulane Educational Fund Methods of inhibiting the ghrelin/growth hormone secretatogue receptor pathway and uses thereof
EP2582715B1 (fr) 2010-06-16 2018-11-28 The Administrators of the Tulane Educational Fund Antagonistes du récepteur du secrétagogue de l'hormone de croissance et leurs utilisations
FR3050112B1 (fr) * 2016-04-15 2020-09-04 Soc Civ Immobiliere Gecinq Utilisation de l'acide fenofibrique dans le traitement des maladies hepatiques
CN107496397A (zh) * 2016-06-14 2017-12-22 重庆安格龙翔医药科技有限公司 一种二甲双胍与非诺贝酸的复合物及其制剂
FR3056908B1 (fr) * 2016-09-30 2019-04-19 Nashpharm Sel de metformine et d'elafibranor presentant une activite duale pour le traitement de l'obesite associee a la steato-hepatite non alcoolique (nash) et a l'hypertriglyceridemie
CN111374093A (zh) * 2018-12-28 2020-07-07 高倩 超级肥胖小鼠的构建与鉴定方法

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2357875A1 (de) * 1973-03-16 1974-09-19 Hurka Wilhelm Clofibrinsaure salze des buformins und/oder metformins, verfahren zu deren herstellung und diese salze enthaltende arzneimittel
JPS51125716A (en) * 1974-06-19 1976-11-02 Cerpha Production of dimethylbiguanide *44chlorphenoxy**isobutylate
WO1998005331A2 (fr) * 1996-08-02 1998-02-12 Ligand Pharmaceuticals Incorporated Prevention ou traitement de diabetes non insulinodependants ou de maladies cardiovasculaires avec des modulateurs ppar
JP2000504021A (ja) * 1996-02-02 2000-04-04 メルク エンド カンパニー インコーポレーテッド 糖尿病及び関連疾患状態を治療する方法
FR2796940A1 (fr) * 1999-07-26 2001-02-02 Lipha Nouveaux sels de metformine, leur procede d'obtention et les compositions pharmaceutiques en renfermant
JP2002502869A (ja) * 1998-02-12 2002-01-29 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング メトホルミンおよびフィブラートとの組み合わせからなる医薬組成物と、高血糖症を緩和するための医薬品製造へのその使用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5190970A (en) * 1990-10-19 1993-03-02 E. R. Squibb & Sons, Inc. Method for preventing onset of or treating Type II diabetes employing a cholesterol lowering drug alone or in combination with an ace inhibitor
US5739106A (en) * 1995-06-07 1998-04-14 Rink; Timothy J. Appetite regulating compositions
US5942500A (en) * 1998-04-27 1999-08-24 Perry; Stephen C. Dietary composition to reduce dietary fats
US6498193B2 (en) * 1999-12-22 2002-12-24 Trustees Of Dartmouth College Treatment for complications of type 2 diabetes
US6569879B2 (en) * 2000-02-18 2003-05-27 Merck & Co., Inc. Aryloxyacetic acids for diabetes and lipid disorders
US20030092736A1 (en) * 2001-05-30 2003-05-15 Cheng Peter T. Substituted azole acid derivatives useful as antidiabetic and antiobesity agents and method
AU2003296895A1 (en) * 2002-08-20 2004-05-04 The Regents Of The University Of California Combination therapy for controlling appetites

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2357875A1 (de) * 1973-03-16 1974-09-19 Hurka Wilhelm Clofibrinsaure salze des buformins und/oder metformins, verfahren zu deren herstellung und diese salze enthaltende arzneimittel
JPS51125716A (en) * 1974-06-19 1976-11-02 Cerpha Production of dimethylbiguanide *44chlorphenoxy**isobutylate
JP2000504021A (ja) * 1996-02-02 2000-04-04 メルク エンド カンパニー インコーポレーテッド 糖尿病及び関連疾患状態を治療する方法
WO1998005331A2 (fr) * 1996-08-02 1998-02-12 Ligand Pharmaceuticals Incorporated Prevention ou traitement de diabetes non insulinodependants ou de maladies cardiovasculaires avec des modulateurs ppar
JP2002502869A (ja) * 1998-02-12 2002-01-29 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング メトホルミンおよびフィブラートとの組み合わせからなる医薬組成物と、高血糖症を緩和するための医薬品製造へのその使用
FR2796940A1 (fr) * 1999-07-26 2001-02-02 Lipha Nouveaux sels de metformine, leur procede d'obtention et les compositions pharmaceutiques en renfermant

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006520365A (ja) * 2003-03-13 2006-09-07 フルニエ ラボラトリーズ アイルランド リミテッド 肥満を治療するための、フィブラート系薬剤及びオルリスタットの使用
JP4928256B2 (ja) * 2003-03-13 2012-05-09 フルニエ ラボラトリーズ アイルランド リミテッド 肥満を治療するための、フィブラート系薬剤及びオルリスタットの使用

Also Published As

Publication number Publication date
CN1777417B (zh) 2010-10-06
WO2004047831A2 (fr) 2004-06-10
CA2507894C (fr) 2011-01-04
EP1424070A1 (fr) 2004-06-02
SI1569634T1 (sl) 2007-10-31
EP1569634B8 (fr) 2007-08-29
ZA200504345B (en) 2006-08-30
CA2507894A1 (fr) 2004-06-10
MA27553A1 (fr) 2005-10-03
EP1569634A2 (fr) 2005-09-07
EP1569634B1 (fr) 2007-05-16
CN1777417A (zh) 2006-05-24
DE60313886D1 (de) 2007-06-28
MXPA05005707A (es) 2005-07-26
BR0316810A (pt) 2005-10-18
US20100144874A1 (en) 2010-06-10
AU2003288175B2 (en) 2008-11-13
DE60313886T2 (de) 2008-01-17
AU2003288175A1 (en) 2004-06-18
ES2287546T3 (es) 2007-12-16
DK1569634T3 (da) 2007-09-10
EA009772B1 (ru) 2008-04-28
HK1077755A1 (en) 2006-02-24
PT1569634E (pt) 2007-08-22
CY1106749T1 (el) 2012-05-23
ATE362362T1 (de) 2007-06-15
WO2004047831A3 (fr) 2005-02-24
US20060142397A1 (en) 2006-06-29
EA200500691A1 (ru) 2005-12-29
NO20052549L (no) 2005-06-10
TNSN05148A1 (fr) 2007-05-14

Similar Documents

Publication Publication Date Title
US20100144874A1 (en) Use of a PPARalpha Agonist and Metformin for Decreasing the Serum Triglycerides
US6207714B1 (en) Methods and pharmaceutical preparations for improving glucose metabolism with (−)-hydroxycitric acid
US20070060532A1 (en) Use of metformin and orlistat for the treatment or prevention of obesity
CA2518205C (fr) Utilisation de fibrate et d'orlistat pour traiter l'obesite
WO2006011495A1 (fr) Remede pour l'hypercholesterolemie et/ou l'hypertriglyceridemie
US20090176835A1 (en) Pharmaceutical composition for suppression of the expression of atp citrate lyase and use thereof
EP1547614B1 (fr) Composition medicinale pour inhiber l'expression d'atp-citrate lyase et son utilisation
JP4588448B2 (ja) PPARγアゴニストによる治療に伴う体重増加を治療するためのPPARαアゴニストの使用
KR20020025066A (ko) HMG-CoA 리덕타제 억제제 및 카르니틴을 포함하는항지질혈성 복합제
EP1388351A1 (fr) Utilisation d'un fibrate pour le traitement d'obesité associée au traitement par le rosiglitazone

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060518

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20060922

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100202

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100506

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20100506

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110105